Authors: H. Sunabe 1; Y. Maezawa 2; T. Shiozawa 3; G. Ohara 2; N. Takayashiki 4; H. Satoh 2 Authors‘ workplace: Division of Respiratory Medicine, Tsukuba Memorial Hospital, Japan 1; Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Japan 2; Faculty of Respiratory Medicine, University of Tsukuba, Tsukuba, Japan 3; Division of Pathology, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Japan 4 Published in: Klin Onkol 2025; 38(6): 484-487 Category: Case Reports doi: https://doi.org/10.48095/ccko2025484
Background: Recently, there has been interest in the CT imaging characteristics of lung cancer positive for mesenchymal-epithelial transition (MET) exon14 skipping mutation. Herein, we present a patient with MET exon 14 skipping gene-positive lung adenocarcinoma associated with multiple ground-glass opacities (GGOs) in both lungs and metachronous contralateral lung adenocarcinoma. Case: A 67-year-old man was referred to our hospital due to abnormal finding on chest radiograph. A chest CT on admission revealed a mass in the right lung. A chest CT scan showed a mass in the middle lobe of the right lung, and numerous GGO nodules of various sizes in both lungs. The mass was resected and it was diagnosed as a MET exon 14 skipping gene-positive invasive adenocarcinoma. A GGO nodule resected at the same time was pathologically diagnosed as atypical adenomatous hyperplasia (AAH). A GGO nodule in the left lung that was present at the initial consultation grew in size on a CT scan performed 1 year and 4 months after the right lung resection, and was therefore resected. The nodule was pathologically diagnosed as a MET exon 14 skipping gene-negative invasive adenocarcinoma. Genetic testing for an AAH adjacent to the second adenocarcinoma was negative for the MET exon 14 skipping gene. Conclusion: The clinical course of this patient was interesting clinical information in terms of providing insight into the morphology, imaging findings, and origin of MET exon 14 skipping gene-positive adenocarcinoma.
lung adenocarcinoma – MET exon 14 skipping gene – atypical adenomatous hyperplasia – double cancers
1. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122 (3): 1450–1459. doi: 10.1016/0006-291x (84) 91253-1.
2. Matsumoto K, Umitsu M, De Silva DM et al. Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci 2017; 108 (3): 296–307. doi: 10.1111/cas.13156.
3. Kong-Beltran M, Seshagiri S, Zha J et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66 (1): 283–289. doi: 10.1158/ 0008-5472.
4. Furqan M, Karanth S, Goyal RK et al. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol 2024; 20 (22): 1553–1563. doi: 10.2217/fon-2023-1064.
5. Frampton GM, Ali SM, Rosenzweig M et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015; 5 (8): 850–859. doi: 10.1158/2159-8290.CD-15-0285.
6. Li S, Choi YL, Gong Z et al. Comprehensive characterization of oncogenic drivers in asian lung adenocarcinoma. Thorac Oncol 2016; 11 (12): 2129–2140. doi: 10.1016/j.jtho.2016.08.142.
7. Mazieres J, Vioix H, Pfeiffer BM et al. MET Exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes. Clin Lung Cancer 2023; 24 (6): 483–497. doi: 10.1016/j.cllc.2023.06.008.
8. Adib E, Nassar AH, Abou Alaiwi S et al. Variation in targetable gnomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Med 2022; 14 (1): 39. doi: 10.1186/s13073-022-01041-x.
9. Watari N, Yamaguchi K, Terada H et al. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer. BMC Pulm Med 2022; 22 (1): 260. doi: 10.1186/s12890-022-02037-4.
10. Washioka A, Akamatsu H, Sugimoto T et al. Invasive mucinous adenocarcinoma harbored MET exon 14 skipping mutation: case report. Transl Lung Cancer Res 2024; 13 (11): 3252–3255. doi: 10.21037/tlcr-24-449.
11. Ikeo S, Yasuda N, Sakai Y et al. Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: a case report. Thorac Cancer 2023; 14 (10): 958–960. doi: 10.1111/1759-7714.14831.
12.Wang SXY, Lei L, Guo HH et al. Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. Lung Cancer 2018; 122 : 187–191. doi: 10.1016/j.lungcan.2018.06.019.
13. Digumarthy SR, Mendoza DP, Zhang EW et al. Clinicopathologic and imaging features of non-small-cell lung cancer with MET Exon 14 skipping mutations. Cancers (Basel) 2019; 11 (12): 2033. doi: 10.3390/cancers11122033.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
